Sumitomo Mitsui Trust Group Inc. Reduces Stock Position in DexCom, Inc. (NASDAQ:DXCM)

Sumitomo Mitsui Trust Group Inc. decreased its holdings in DexCom, Inc. (NASDAQ:DXCM) by 0.4% during the fourth quarter, HoldingsChannel.com reports. The firm owned 945,885 shares of the medical device company’s stock after selling 3,680 shares during the quarter. Sumitomo Mitsui Trust Group Inc.’s holdings in DexCom were worth $73,561,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also made changes to their positions in the company. Versant Capital Management Inc purchased a new position in DexCom in the 4th quarter worth about $25,000. Riverview Trust Co increased its position in shares of DexCom by 100.4% during the third quarter. Riverview Trust Co now owns 463 shares of the medical device company’s stock worth $31,000 after acquiring an additional 232 shares during the period. Heck Capital Advisors LLC bought a new stake in shares of DexCom during the fourth quarter valued at approximately $38,000. MassMutual Private Wealth & Trust FSB boosted its holdings in shares of DexCom by 46.7% in the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 833 shares of the medical device company’s stock valued at $65,000 after purchasing an additional 265 shares during the period. Finally, RPg Family Wealth Advisory LLC bought a new position in DexCom in the third quarter worth approximately $57,000. 97.75% of the stock is currently owned by institutional investors.

DexCom Trading Down 0.3 %

Shares of NASDAQ:DXCM opened at $88.08 on Monday. The company has a current ratio of 2.46, a quick ratio of 2.12 and a debt-to-equity ratio of 1.23. DexCom, Inc. has a 12-month low of $62.34 and a 12-month high of $142.00. The business has a 50 day moving average of $81.76 and a two-hundred day moving average of $75.36. The company has a market capitalization of $34.40 billion, a PE ratio of 52.74, a PEG ratio of 2.26 and a beta of 1.14.

Insider Activity

In other DexCom news, EVP Jereme M. Sylvain sold 2,090 shares of DexCom stock in a transaction on Wednesday, January 29th. The shares were sold at an average price of $86.91, for a total value of $181,641.90. Following the completion of the transaction, the executive vice president now owns 83,526 shares of the company’s stock, valued at approximately $7,259,244.66. The trade was a 2.44 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, COO Jacob Steven Leach sold 2,634 shares of the company’s stock in a transaction dated Wednesday, January 29th. The stock was sold at an average price of $86.91, for a total transaction of $228,920.94. Following the completion of the transaction, the chief operating officer now owns 268,644 shares of the company’s stock, valued at approximately $23,347,850.04. This trade represents a 0.97 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 42,342 shares of company stock valued at $3,628,069 in the last three months. 0.30% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

DXCM has been the subject of a number of research analyst reports. JPMorgan Chase & Co. lifted their target price on DexCom from $75.00 to $85.00 and gave the company a “neutral” rating in a research report on Friday, October 25th. Citigroup lifted their price target on shares of DexCom from $85.00 to $91.00 and gave the stock a “buy” rating in a report on Wednesday, December 11th. Raymond James cut their price objective on shares of DexCom from $115.00 to $99.00 and set a “strong-buy” rating on the stock in a report on Friday, October 25th. Robert W. Baird upgraded shares of DexCom from a “neutral” rating to an “outperform” rating and lifted their target price for the stock from $86.00 to $104.00 in a research note on Thursday, January 16th. Finally, Sanford C. Bernstein boosted their target price on shares of DexCom from $82.00 to $86.00 and gave the stock an “outperform” rating in a research report on Friday, October 25th. Four investment analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat, DexCom currently has a consensus rating of “Moderate Buy” and a consensus price target of $98.41.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.